Medical devices; reclassification of tumor-associated antigen immunological test system--FDA. Final rule.
The Food and Drug Administration (FDA) is announcing that it is codifying the reclassification of tumor-associated antigen immunological test systems intended as an aid in monitoring patients for disease progression or response to therapy or for the detection of recurrent or residual disease from class III (premarket approval) to class II (special controls). FDA is also announcing that it has issued an order in the form of a letter to Centocar, Inc., reclassifying serum tumor markers into class II. This action is being taken under the Federal Food, Drug, and Cosmetic Act (the act), as amended by the Medical Device Amendments of 1976 and the Safe Medical Devices Act of 1990.
D000951:Antigens, Neoplasm / Q000145:classification*; D014408:Biomarkers, Tumor / Q000145:classification* / Q000592:standards; D018450:Disease Progression; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D014481:United States; D014486:United States Food and Drug Administration